178 related articles for article (PubMed ID: 11035738)
1. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.
Murray HW
Infect Immun; 2000 Nov; 68(11):6294-9. PubMed ID: 11035738
[TBL] [Abstract][Full Text] [Related]
2. Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.
Murray HW; Luster AD; Zheng H; Ma X
Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795366
[TBL] [Abstract][Full Text] [Related]
3. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
Murray HW; Delph-Etienne S
Infect Immun; 2000 Jan; 68(1):288-93. PubMed ID: 10603400
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
Murray HW; Montelibano C; Peterson R; Sypek JP
J Infect Dis; 2000 Nov; 182(5):1497-502. PubMed ID: 11023473
[TBL] [Abstract][Full Text] [Related]
5. Tissue granuloma structure-function in experimental visceral leishmaniasis.
Murray HW
Int J Exp Pathol; 2001 Oct; 82(5):249-67. PubMed ID: 11703536
[TBL] [Abstract][Full Text] [Related]
6. Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent.
Murray HW; Granger AM; Mohanty SK
J Infect Dis; 1991 Mar; 163(3):622-4. PubMed ID: 1899875
[TBL] [Abstract][Full Text] [Related]
7. Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.
Murray HW; Hariprashad J; McDermott DF; Stoeckle MY
Infect Immun; 1996 Jan; 64(1):161-6. PubMed ID: 8557335
[TBL] [Abstract][Full Text] [Related]
8. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis.
Murray HW
J Immunol; 2005 Apr; 174(8):4916-23. PubMed ID: 15814719
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 155 Contributes to Host Immunity against Leishmania donovani but Is Not Essential for Resolution of Infection.
Varikuti S; Natarajan G; Volpedo G; Singh B; Hamza O; Messick GV; Guerau-de-Arellano M; Papenfuss TL; Oghumu S; Satoskar AR
Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31182615
[TBL] [Abstract][Full Text] [Related]
10. Effector role of blood monocytes in experimental visceral leishmaniasis.
Cervia JS; Rosen H; Murray HW
Infect Immun; 1993 Apr; 61(4):1330-3. PubMed ID: 8454335
[TBL] [Abstract][Full Text] [Related]
11. Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice.
Squires KE; Kirsch M; Silverstein SC; Acosta A; McElrath MJ; Murray HW
Infect Immun; 1990 Dec; 58(12):3893-8. PubMed ID: 2123825
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
Murray HW; Jungbluth A; Ritter E; Montelibano C; Marino MW
Infect Immun; 2000 Nov; 68(11):6289-93. PubMed ID: 11035737
[TBL] [Abstract][Full Text] [Related]
13. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.
Murray HW; Lu CM; Brooks EB; Fichtl RE; DeVecchio JL; Heinzel FP
Infect Immun; 2003 Nov; 71(11):6453-62. PubMed ID: 14573667
[TBL] [Abstract][Full Text] [Related]
14. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
Murray HW; Lu CM; Mauze S; Freeman S; Moreira AL; Kaplan G; Coffman RL
Infect Immun; 2002 Nov; 70(11):6284-93. PubMed ID: 12379707
[TBL] [Abstract][Full Text] [Related]
16. Role and effect of IL-2 in experimental visceral leishmaniasis.
Murray HW; Miralles GD; Stoeckle MY; McDermott DF
J Immunol; 1993 Jul; 151(2):929-38. PubMed ID: 8335921
[TBL] [Abstract][Full Text] [Related]
17. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis.
Murray HW; Cervia JS; Hariprashad J; Taylor AP; Stoeckle MY; Hockman H
J Clin Invest; 1995 Mar; 95(3):1183-92. PubMed ID: 7883967
[TBL] [Abstract][Full Text] [Related]
18. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.
Murray HW
Infect Immun; 2008 Sep; 76(9):4088-91. PubMed ID: 18573898
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.
Murray HW; Hariprashad J; Fichtl RE
Antimicrob Agents Chemother; 1993 Jul; 37(7):1504-5. PubMed ID: 8363382
[TBL] [Abstract][Full Text] [Related]
20. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice.
Taylor AP; Murray HW
J Exp Med; 1997 Apr; 185(7):1231-9. PubMed ID: 9104810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
